Scarica l'app Stockscreener
16.48
4.52%
-0.78
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$17.26
Aprire:
$17.165
Volume 24 ore:
9.82M
Relative Volume:
0.88
Capitalizzazione di mercato:
$19.19B
Reddito:
$14.57B
Utile/perdita netta:
$-296.50M
Rapporto P/E:
-63.63
EPS:
-0.259
Flusso di cassa netto:
$1.64B
1 W Prestazione:
-4.02%
1M Prestazione:
+18.90%
6M Prestazione:
+53.73%
1 anno Prestazione:
+87.49%
Intervallo 1D:
$16.40
$17.17
Intervallo di 1 settimana:
$16.40
$17.53
Portata 52W:
$8.19
$17.53
Viatris Inc Stock (VTRS) Company Profile
Nome
Viatris Inc
Settore
Telefono
(724) 514-1465
Indirizzo
1000 MYLAN BOULEVARD, CANONSBURG
Compare VTRS vs TAK, TEVA, HLN, ZTS, UTHR
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
VTRS
Viatris Inc
|
16.48 | 20.10B | 14.57B | -296.50M | 1.64B | -0.259 |
TAK
Takeda Pharmaceutical Co Adr
|
16.61 | 52.55B | 29.91B | 1.30B | 3.49B | 0.4056 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
34.29 | 41.12B | 17.53B | 1.58B | 444.18M | 1.3457 |
HLN
Haleon Plc Adr
|
8.96 | 39.50B | 14.54B | 2.22B | 2.58B | 0.4871 |
ZTS
Zoetis Inc
|
74.22 | 31.64B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
568.58 | 24.44B | 3.17B | 1.29B | 1.01B | 27.09 |
Viatris Inc Stock (VTRS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-02-09 | Aggiornamento | UBS | Neutral → Buy |
| 2026-01-16 | Aggiornamento | Argus | Hold → Buy |
| 2025-12-09 | Iniziato | Barclays | Overweight |
| 2025-10-15 | Iniziato | Truist | Buy |
| 2025-06-06 | Iniziato | Goldman | Neutral |
| 2024-07-19 | Ripresa | Jefferies | Buy |
| 2023-10-23 | Downgrade | BofA Securities | Neutral → Underperform |
| 2023-06-23 | Downgrade | Barclays | Equal Weight → Underweight |
| 2023-04-24 | Downgrade | Barclays | Overweight → Equal Weight |
| 2023-02-17 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2023-01-27 | Aggiornamento | Jefferies | Hold → Buy |
| 2022-11-10 | Aggiornamento | UBS | Sell → Neutral |
| 2022-11-08 | Aggiornamento | Piper Sandler | Underweight → Neutral |
| 2022-10-21 | Ripresa | Jefferies | Hold |
| 2022-06-14 | Iniziato | UBS | Sell |
| 2022-05-10 | Downgrade | Piper Sandler | Neutral → Underweight |
| 2022-03-01 | Downgrade | BofA Securities | Buy → Neutral |
| 2022-03-01 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2021-06-15 | Iniziato | Citigroup | Neutral |
| 2021-04-07 | Ripresa | RBC Capital Mkts | Outperform |
| 2021-03-08 | Downgrade | Goldman | Buy → Neutral |
| 2021-03-02 | Downgrade | JP Morgan | Overweight → Neutral |
| 2021-02-26 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| 2021-01-05 | Iniziato | Argus | Hold |
| 2020-12-14 | Iniziato | Bernstein | Mkt Perform |
Mostra tutto
Viatris Inc Borsa (VTRS) Ultime notizie
Understanding Momentum Shifts in (VTRS) - Stock Traders Daily
Viatris Inc (VTRS) Stock Down 4.5% but Still Overvalued -- GF Sc - GuruFocus
Viatris Shareholders Approve Directors, Pay and Auditor - TipRanks
Viatris Inc. stock falls Friday, underperforms market - MarketWatch
Viatris (VTRS) investors elect full board and approve 2025 pay, auditor - Stock Titan
Viatris CFO leaving Canonsburg pharma giant - MSN
Bacterial Vaginosis Drug Market Will Generate Booming Growth - openPR.com
Viatris Inc.Common Stock (NQ: VTRS - FinancialContent
Biosimilars Market is expected to Hit US$ 99.3 Billion by 2033 | - openPR.com
5 Revealing Analyst Questions From Viatris’s Q1 Earnings Call - The Globe and Mail
Fed. Circ. Won't Save Actelion's Suit Over Hypertension Drug - Law360
Viatris Inc. stock rises Wednesday, outperforms market - MarketWatch
Earnings call transcript: Viatris Q1 2026 beats EPS forecast, stock rises - Investing.com
Earnings call transcript: Viatris Q1 2026 beats EPS forecast, stock rises By Investing.com - Investing.com South Africa
Viatris Hypertension Drug Doesn’t Copy J&J Patents, Court Says - Bloomberg Law News
Why Viatris (VTRS) is a Top Value Stock for the Long-Term - sharewise.com
HHS officials considered banning SSRI antidepressantsreport - MSN
Viatris (VTRS) Is Up 10.6% After Q1 Beat, CFO Change And Outlook ReaffirmationWhat's Changed - simplywall.st
Viatris Inc. stock rises Tuesday, outperforms market - MarketWatch
Transcript : Viatris Inc. Presents at Bank of America Global Healthcare Conference 2026, May-12-2026 08 - marketscreener.com
Why Viatris (VTRS) is a Top Growth Stock for the Long-Term - Yahoo Finance
Viatris: From Cost Story To Pipeline-Driven Re-Rating (Rating Upgrade) (NASDAQ:VTRS) - Seeking Alpha
VTRS Q1 Deep Dive: China Strength, R&D Pipeline, and Execution Drive Outperformance - Yahoo Finance
Viatris Inc. stock falls Monday, underperforms market - MarketWatch
Viatris gears up to report Q1 earnings: What's in the cards? - MSN
Presbyopia Market to Witness Accelerated Growth at a CAGR of 4.9% During the Forecast Period (2026–2036) Supported by Expanding Treatment Landscape | DelveInsight - GlobeNewswire Inc.
Viatris: The Cigar Butt Got Smoked, But I'm Holding The Rating (NASDAQ:VTRS) - Seeking Alpha
UBS Adjusts Viatris Price Target to $23 From $20 - Moomoo
Viatris Inc. (VTRS) Stock Analysis: Exploring the Healthcare Giant’s Valuation and Dividend Yield - DirectorsTalk Interviews
Viatris Announces Second Quarter 2024 Dividend - Quantisnow
Viatris Q1 2026 earnings preview: Caution remains around ongoing turnaround - MSN
Viatris Inc. stock rises Thursday, outperforms market - MSN
Viatris Inc. (NASDAQ:VTRS) Q1 2026 Earnings Call Transcript - Insider Monkey
Viatris Earnings Call Highlights Profits, Pipeline Momentum - The Globe and Mail
Research Alert: CFRA Keeps Hold Opinion On Shares Of Viatris Inc. - Moomoo
symbol__ Stock Quote Price and Forecast - CNN
TBPH Q1 Earnings Beat Amid Strategic Restructuring & Pipeline Hurdle - TradingView
Truist Financial Maintains Viatris(VTRS.US) With Buy Rating, Announces Target Price $20 - Moomoo
Hypercholesterolemia Treatment Market is expected to Hit US$ - openPR.com
Viatris: Q1 Earnings Snapshot - theheraldreview.com
Viatris Inc. Stock 12‑Month Price Target Raised to $17.25, Implies 1% Downside - TradingView
Viatris to Present at the Bank of America Securities 2026 Healthcare Conference - BioSpace
Viatris (VTRS) Heavy FY 2025 Losses Keep Bullish Turnaround Narratives Under Pressure - Sahm
Viatris Inc. Stock 12‑Month Price Target Raised to $16.88, Implies 3% Downside - TradingView
5-Day Rally Sends Viatris Stock Up 16% - Trefis
Viatris Stock Rockets 16% With 5-Day Winning Streak - Trefis
Viatris stock hits 52-week high at $16.63 By Investing.com - Investing.com Nigeria
Viatris Q1 2026 Earnings Call Transcript - MarketBeat
Viatris Inc. Q1 2026 Earnings Call Summary - Yahoo Finance
Viatris (VTRS) Jumps As Targets Rise And Pipeline Delivers - timothysykes.com
Viatris to Present at the Bank of America Securities 2026 Healthcare Conference – Company Announcement - Financial Times
Viatris Inc Azioni (VTRS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.40%
6.21%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):